Clinical observation and follow-up study on oxaliplatin-related neurotoxicity in patients with resectable colorectal cancer

Chinese Journal of Clinical Oncology

Volumn 40, Issue 12, 2013, Pages 725-729

  Liu, Huilong ^a   Wang, Li ^a   Jia, Jia ^a   Liu, Yanfang ^a   Wang, Fei ^a   Li, Hongying ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; Neurotoxicity; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACUTE NEUROTOXICITY; ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CHRONIC NEUROTOXICITY; CLINICAL ASSESSMENT; CLINICAL OBSERVATION; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NEUROTOXICITY; NTX 12; QUESTIONNAIRE; TREATMENT DURATION;

EID: 84885169795     PISSN: 10008179     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2013.12.011     Document Type: Article

References (16)

1. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatinas first-line therapy for metastatic colorectal cancer[J]. J Clin Oncol, 2008, 26(12):2006-2012.
2. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients withresected stage III colon cancer: a randomized trial[J]. JAMA, 2012, 307(13):1383-1393.
3. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advancedcolorectal cancer - a GERCOR study[J]. J Clin Onco, 2006, 24(3):394-400.
4. Nakayama G, Uehara K, Ishigure K, et al. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801) [J]. Cancer Chemother Pharmacol, 2012, 70(4):575-581.
5. Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for coloncancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01[J]. Cancer, 2012, 118(22):5614-5622.
6. Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane(FACT-taxane)[J]. Cancer, 2003, 98(4):822-831. (Pubitemid 36959280)
7. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer[J]. J Clin Oncol, 2011, 29(11):1465-1471.
8. Baek KK, Lee J, Park SH, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer[J]. Cancer Res Treat, 2010, 42(4):185-190.
9. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current[J]. Proc Natl Acad Sci U S A, 2012, 109(17):6704-6709.
10. Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility[J]. Oncologist, 2011, 16(5):708-716.
11. Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity[J]. J Clin Oncol, 2009, 27(8):1243-1249.
12. Khattak MA. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity[J]? Oncologist, 2011, 16(12):1780-1783.
13. Ao R, Wang YH, Li RW, et al. Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: A meta-analysis[J]. Exp Ther Med, 2012, 4(5):933-937.
14. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27(19):3109-3116.
15. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III coloncancer[J]. J Natl Cancer Inst, 2012, 104(3):211-227.